Outlook Therapeutics Reports $11.2M Cash; FDA Approves LYTENAVA

What Happened

• Outlook Therapeutics, Inc. filed a Form 8-K on August 12, 2026 announcing two primary items: a preliminary cash balance and a material corporate update tied to a recent FDA approval.
• The company reported that, based on preliminary estimates, it had approximately $11.2 million in cash and cash equivalents as of June 30, 2026 (unaudited and subject to closing and review). The filing cautions actual results for the quarter may differ materially once finalized.
• Separately, Outlook announced that the U.S. Food and Drug Administration approved LYTENAVA™ (bevacizumab‑vikg) for treatment of neovascular age-related macular degeneration (nAMD) on July 24, 2026. The company also amended and restated its risk factors to reflect this development and related considerations. On August 10, 2026 Outlook terminated the prospectus supplement dated May 13, 2026 relating to its At‑The‑Market (ATM) Sales Agreement with H.C. Wainwright; the Sales Agreement itself remains in effect but no sales will occur until a new prospectus supplement is filed.

Key Details

• Preliminary cash and cash equivalents as of June 30, 2026: approximately $11.2 million (unaudited; subject to change).
• FDA approval date for LYTENAVA (bevacizumab‑vikg) for nAMD: July 24, 2026.
• Prospectus supplement for the May 13, 2026 ATM Sales Agreement with H.C. Wainwright was terminated on August 10, 2026; no ATM sales until a new prospectus supplement is filed. Sales Agreement remains in force.
• Company filed amended and restated risk factors (Exhibit 99.1) to replace prior risk disclosures in its 2025 Form 10‑K.

Why It Matters

• The preliminary cash figure gives investors an early view of liquidity going into Q3 2026; because it is unaudited and preliminary, final quarterly results could change and affect runway assumptions.
• FDA approval of LYTENAVA is a significant regulatory milestone that could materially affect Outlook’s commercial prospects, revenue potential, and risk profile; the company updated its risk disclosures accordingly.
• The termination of the existing prospectus supplement means Outlook will not raise capital through the ATM program until it files a new prospectus supplement, although the Sales Agreement itself could be used in the future. Investors should watch for the finalized quarterly report and any filings on commercialization plans, revenue guidance, or new financing arrangements.